Sam Ricchezza

is the Vice President, Business Development for WellSpring Pharma Services. He has over 18 years of business development and marketing experience in the pharmaceutical contract development and manufacturing industry. He has held a number of progressively responsible business development positions over the course of his career with Patheon, DPT Laboratories, AAIPharma and WellSpring. Sam is also a member of “Contract Pharma’s” Editorial Advisory Board.
Find me on:

Recent Posts

Canada’s Winning Business and Regulatory Climate

Posted by Sam Ricchezza

Doing business in Canada offers tangible business benefits. In any country, contracting contract manufacturing services requires managing the legal and regulatory aspects particular to that country; fortunately maintaining a commercial relationship across Canadian borders is generally simple and straightforward. Canada offers pharma companies an ideal platform from which to access European and other markets as part of an international business strategy. 

more

Topics: CMO Partner, open market, regulation, innovation

Quality Assessment – Quality Metrics That Truly Matter

Posted by Sam Ricchezza

What elements comprise a “quality” quality assessment in the pharmaceutical industry? Which metrics matter the most? Evaluating the quality or operational excellence across a contract pharmaceutical manufacturing organization is one of the most critical aspects of vetting prospective contract manufacturing partners.

more

Topics: Quality Assurance, Quality Control, CMO

Canada: A Good Place for Pharmaceutical Manufacturing, No Matter Where You Are

Posted by Sam Ricchezza

Canada’s pharmaceutical sector is one of the country’s most innovative industries. Comprised of companies developing new and generic prescription pharmaceuticals and biopharmaceuticals as well as over-the-counter drug products, the sector also includes contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) such as WellSpring. A lucrative market in its own right, Canada claims a 2.5 percent share of the global pharmaceutical market, making it the ninth largest in the world (IMS Health Pharmafocus 2018).

more

Topics: Partner Relationships

3 Common Problems Between Pharmaceutical Companies and Contract Manufacturing Organizations (CMOs)

Posted by Sam Ricchezza

pharma-companies-supplier-relationshipsIt is not uncommon for pharmaceutical companies to come to us looking to change their CMO relationship, usually due to a relationship issue that goes unchecked by both sides.  When issues are not highlighted by either the client or the CMO and tabled for discussion at the appropriate time, they tend to fester and irritate one side, the other or both.  You can tell when a relationship begins to sour, usually by the lack of responsiveness in communication or uncooperativeness in dealing with project tasks or quality-related items.  When this begins to happen, don’t be too surprised if a client starts looking for alternative supply sources.

From our experience, there are really three main sources of relationship problems between clients and CMO’s. These are:

more

Topics: Partner Relationships